DBV Technologies (DBVT) Competitors $4.39 +0.13 (+3.05%) Closing price 02/21/2025 03:55 PM EasternExtended Trading$4.42 +0.03 (+0.77%) As of 02/21/2025 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends DBVT vs. MBX, CYRX, CRVS, MNPR, PRME, ATYR, TRVI, ALLO, CMPS, and KRROShould you be buying DBV Technologies stock or one of its competitors? The main competitors of DBV Technologies include MBX Biosciences (MBX), Cryoport (CYRX), Corvus Pharmaceuticals (CRVS), Monopar Therapeutics (MNPR), Prime Medicine (PRME), Atyr PHARMA (ATYR), Trevi Therapeutics (TRVI), Allogene Therapeutics (ALLO), COMPASS Pathways (CMPS), and Korro Bio (KRRO). These companies are all part of the "pharmaceutical products" industry. DBV Technologies vs. MBX Biosciences Cryoport Corvus Pharmaceuticals Monopar Therapeutics Prime Medicine Atyr PHARMA Trevi Therapeutics Allogene Therapeutics COMPASS Pathways Korro Bio MBX Biosciences (NYSE:MBX) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, community ranking, dividends, media sentiment, institutional ownership, profitability, valuation and earnings. Do institutionals & insiders have more ownership in MBX or DBVT? 71.7% of DBV Technologies shares are held by institutional investors. 1.9% of DBV Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts rate MBX or DBVT? MBX Biosciences presently has a consensus target price of $37.25, indicating a potential upside of 242.37%. DBV Technologies has a consensus target price of $22.50, indicating a potential upside of 412.53%. Given DBV Technologies' higher probable upside, analysts clearly believe DBV Technologies is more favorable than MBX Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MBX Biosciences 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00DBV Technologies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to MBX or DBVT? In the previous week, MBX Biosciences had 6 more articles in the media than DBV Technologies. MarketBeat recorded 8 mentions for MBX Biosciences and 2 mentions for DBV Technologies. MBX Biosciences' average media sentiment score of 1.62 beat DBV Technologies' score of 0.55 indicating that MBX Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive DBV Technologies 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation & earnings, MBX or DBVT? MBX Biosciences has higher earnings, but lower revenue than DBV Technologies. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMBX BiosciencesN/AN/AN/AN/AN/ADBV Technologies$15.73M5.74-$72.73M-$4.50-0.98 Is MBX or DBVT more profitable? MBX Biosciences has a net margin of 0.00% compared to DBV Technologies' net margin of -815.73%. MBX Biosciences' return on equity of 0.00% beat DBV Technologies' return on equity.Company Net Margins Return on Equity Return on Assets MBX BiosciencesN/A N/A N/A DBV Technologies -815.73%-106.07%-76.17% Does the MarketBeat Community believe in MBX or DBVT? DBV Technologies received 401 more outperform votes than MBX Biosciences when rated by MarketBeat users. However, 100.00% of users gave MBX Biosciences an outperform vote while only 54.73% of users gave DBV Technologies an outperform vote. CompanyUnderperformOutperformMBX BiosciencesOutperform Votes4100.00% Underperform VotesNo VotesDBV TechnologiesOutperform Votes40554.73% Underperform Votes33545.27% SummaryMBX Biosciences beats DBV Technologies on 7 of the 12 factors compared between the two stocks. Get DBV Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for DBVT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DBVT vs. The Competition Export to ExcelMetricDBV TechnologiesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$90.30M$3.13B$5.77B$8.98BDividend YieldN/A1.57%4.78%3.85%P/E Ratio-0.9830.1126.4618.82Price / Sales5.74386.80455.0280.40Price / CashN/A183.5344.0437.47Price / Book0.603.567.634.64Net Income-$72.73M-$71.72M$3.18B$245.69M7 Day PerformanceN/A-2.46%-1.91%-2.66%1 Month Performance-7.38%-0.25%-0.19%-2.15%1 Year Performance-46.85%-12.31%16.70%12.90% DBV Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DBVTDBV Technologies3.6686 of 5 stars$4.39+3.1%$22.50+412.5%-45.9%$90.30M$15.73M-0.9880Analyst ForecastMBXMBX Biosciences2.59 of 5 stars$10.27-16.7%$37.25+262.6%N/A$343.36MN/A0.0036Insider TradeNews CoverageHigh Trading VolumeCYRXCryoport2.5802 of 5 stars$6.81flat$12.29+80.4%-61.4%$336.62M$233.26M-2.011,170Positive NewsCRVSCorvus Pharmaceuticals1.9049 of 5 stars$5.04-3.4%$12.38+145.8%+82.2%$323.55MN/A-5.4130News CoverageMNPRMonopar Therapeutics0.9208 of 5 stars$52.16+7.6%$43.00-17.6%+1,312.3%$318.15MN/A-26.4710PRMEPrime Medicine2.5319 of 5 stars$2.42-2.0%$13.13+442.4%-65.1%$317.41MN/A-1.18234News CoverageATYRAtyr PHARMA2.8189 of 5 stars$3.78-3.2%$19.25+409.9%N/A$316.87M$350,000.00-4.0253Analyst ForecastAnalyst RevisionNews CoverageGap UpTRVITrevi Therapeutics2.7567 of 5 stars$4.06-4.4%$9.31+129.7%+73.6%$311.71MN/A-9.2220News CoveragePositive NewsGap UpALLOAllogene Therapeutics2.8233 of 5 stars$1.49-1.7%$9.73+555.4%-51.1%$311.36M$90,000.00-0.95310Gap UpCMPSCOMPASS Pathways1.7049 of 5 stars$4.48+1.5%$33.60+650.8%-57.6%$306.18MN/A-2.03120KRROKorro Bio0.917 of 5 stars$32.26-6.8%$144.00+346.4%-51.4%$302.28MN/A0.0070News CoverageGap Up Related Companies and Tools Related Companies MBX Biosciences Alternatives Cryoport Alternatives Corvus Pharmaceuticals Alternatives Monopar Therapeutics Alternatives Prime Medicine Alternatives Atyr PHARMA Alternatives Trevi Therapeutics Alternatives Allogene Therapeutics Alternatives COMPASS Pathways Alternatives Korro Bio Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DBVT) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DBV Technologies S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share DBV Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DBVT Stock Alerts